Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Precision Medicine
- Omics technologies
- Artificial Intelligence (AI) in Precision Medicine and drug discovery
- Benefits of the use of Artificial Intelligence in drug discovery
- Challenges in the use of Artificial Intelligence in standard clinical practice
Biography
Dr. Michael P. Menden is a Junior Group Leader at the Institute of Computational Biology (Helmholtz Zentrum München) since 2019, and is heading the Menden Lab, and is Head of the DZD Computational Biology Unit. He was awarded an ERC Starting Grant in 2020. Previously, Dr. Menden worked as Senior Scientist in Oncology Bioinformatics, AstraZeneca, UK.
He was a PhD student and postdoctoral fellow at EMBL-EBI, UK. His PhD was awarded in Computational Biology by the University of Cambridge, UK in 2016. In 2017, Dr. Menden was appointed an Honorary Lecturer position at the University of Sheffield, UK. Since 2019, Dr. Menden also became a lecturer in the Technical University of Munich (TUM) and Ludwig Maximilian University (LMU).
Links
Series:
Categories:
External Links
Talk Citation
Menden, M.P. (2022, January 6). Artificial intelligence in precision medicine [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 8, 2023, from https://hstalks.com/bs/4864/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael P. Menden has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Artificial intelligence in precision medicine
Published on January 6, 2022
14 min
Other Talks in the Series: Research and Clinical Interviews
Transcript
0:00
Interviewer: Dr. Michael Menden, thank you for recording this interview with us today on artificial intelligence and precision medicine.
The concept of precision medicine was introduced almost two decades ago,
to address the need of more tailored treatment options based on patients molecular profile,
lifestyle and environmental factors.
Since the introduction of this concept,
how much has changed in the traditional drug discovery process,
and how much has much this impacted the pharmaceutical industry?
Dr. Menden: Thank you very much for the question.
We have to acknowledge drug development is slow,
and precision medicine has been able to accelerate drug approval.
Therefore, it's a very viable concept,
a very important concept for pharmaceutical companies to implement.
Nowadays, when you develop a new drug from the beginning,
you're always on the hunt for biomarkers and how to stratify your patients later on.
Companion diagnostics are often developed with a drug at the same time from the very beginning.
This concept of precision medicine to stratify your patient or respondent,
or non-respondent, based on molecular characterization has been pioneered by oncology.
Just, let me give you a few examples of trastuzumab.
For example, there is a drug developed by Rush,
which is targeting HER-2 amplification in breast cancer.
They made it to the market in 11 years after discovery of this oncogenic event,
and roughly 20 percent of all breast cancer patients have a HER-2 amplification,
so there's a high need to actually target this.
Another example is BRAF V600E mutations in melanoma and skin cancer,
and those are abundant in approximately 60 percent of all skin cancer patients.